Ubs Group Ag Aclaris Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 31,852 shares of ACRS stock, worth $78,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,852

Previous 33,791 5.74%

Holding current value

$78,992

Previous $37,000 5.41%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.4 $2,171 - $2,714	-1,939 Reduced 5.74%	31,852 $35,000
Q2 2024 Aug 13, 2024	SELL	$1.01 - $1.36 $36,976 - $49,789	-36,610 Reduced 52.0%	33,791 $37,000
Q1 2024 May 13, 2024	BUY	$0.92 - $1.44 $46,714 - $73,118	50,777 Added 258.75%	70,401 $87,000
Q4 2023 Feb 09, 2024	SELL	$0.64 - $6.49 $20,514 - $208,030	-32,054 Reduced 62.03%	19,624 $20,000
Q3 2023 Nov 09, 2023	BUY	$6.56 - $10.95 $320,547 - $535,060	48,864 Added 1736.46%	51,678 $353,000
Q2 2023 Aug 11, 2023	BUY	$7.89 - $10.64 $6,162 - $8,309	781 Added 38.42%	2,814 $29,000
Q1 2023 May 12, 2023	SELL	$7.07 - $17.95 $2,637 - $6,695	-373 Reduced 15.5%	2,033 $16,000
Q4 2022 Feb 08, 2023	SELL	$14.33 - $18.37 $6,663 - $8,542	-465 Reduced 16.2%	2,406 $37,000
Q3 2022 Nov 10, 2022	BUY	$13.07 - $18.22 $6,077 - $8,472	465 Added 19.33%	2,871 $45,000
Q2 2022 Aug 10, 2022	BUY	$10.16 - $17.08 $7,152 - $12,024	704 Added 41.36%	2,406 $34,000
Q1 2022 May 16, 2022	SELL	$9.74 - $17.92 $433,293 - $797,189	-44,486 Reduced 96.32%	1,702 $29,000
Q4 2021 Feb 14, 2022	BUY	$12.27 - $18.49 $546,481 - $823,507	44,538 Added 2699.27%	46,188 $671,000
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $16,711 - $23,481	-1,249 Reduced 43.08%	1,650 $30,000
Q2 2021 Aug 13, 2021	SELL	$17.08 - $29.6 $59,216 - $102,623	-3,467 Reduced 54.46%	2,899 $51,000
Q1 2021 May 12, 2021	BUY	$5.86 - $27.73 $29,651 - $140,313	5,060 Added 387.44%	6,366 $160,000
Q4 2020 Feb 11, 2021	SELL	$2.65 - $7.61 $9,831 - $28,233	-3,710 Reduced 73.96%	1,306 $8,000
Q3 2020 Nov 12, 2020	BUY	$1.5 - $2.71 $6,703 - $12,110	4,469 Added 817.0%	5,016 $13,000
Q2 2020 Jul 31, 2020	SELL	$1.04 - $1.73 $19,188 - $31,918	-18,450 Reduced 97.12%	547 $1,000
Q1 2020 May 01, 2020	SELL	$0.75 - $2.18 $14,106 - $41,003	-18,809 Reduced 49.75%	18,997 $20,000
Q4 2019 Feb 14, 2020	BUY	$1.02 - $1.97 $29,323 - $56,635	28,749 Added 317.42%	37,806 $71,000
Q3 2019 Nov 14, 2019	SELL	$0.79 - $2.47 $716,921 - $2.24 Million	-907,495 Reduced 99.01%	9,057 $10,000
Q2 2019 Aug 14, 2019	BUY	$2.13 - $7.06 $496,317 - $1.65 Million	233,013 Added 34.09%	916,552 $2.01 Million
Q1 2019 May 14, 2019	SELL	$5.63 - $7.84 $3.57 Million - $4.97 Million	-633,721 Reduced 48.11%	683,539 $4.09 Million
Q4 2018 Feb 14, 2019	BUY	$6.3 - $15.4 $8.3 Million - $20.3 Million	1,317,241 Added 6932847.5%	1,317,260 $9.73 Million
Q2 2018 Aug 14, 2018	SELL	$16.46 - $20.33 $39,734 - $49,076	-2,414 Reduced 99.22%	19 $0
Q1 2018 May 15, 2018	SELL	$17.08 - $25.64 $4,440 - $6,666	-260 Reduced 9.65%	2,433 $43,000
Q4 2017 Feb 14, 2018	SELL	$21.47 - $27.8 $72,182 - $93,463	-3,362 Reduced 55.52%	2,693 $66,000
Q3 2017 Nov 14, 2017	BUY	$23.02 - $28.8 $63,719 - $79,718	2,768 Added 84.21%	6,055 $156,000
Q2 2017 Aug 14, 2017	SELL	N/A	-1,175 Reduced 26.33%	3,287 $90,000
Q1 2017 Nov 14, 2017	BUY	N/A	4,462	4,462 $133,000

Others Institutions Holding ACRS

# of Institutions

Shares Held

50.7M

Call Options Held

30.6K

Put Options Held

View Full List

About Aclaris Therapeutics, Inc.

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $165M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

More about ACRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account